Biotech Investing

By Peak Bggr

Investing
Opinion: 5 biotech stocks that could be the next big winners
MarketWatch - By Jeff Reeves
Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, …
Investing
In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?
Seeking Alpha - Nicholas Pugliese
Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn …
Investing
Biogen Stock Likely Won’t See a Boost From Buybacks, Analysts Say
Barron's - Teresa Rivas
Text size Biogen stock (ticker: BIIB) is taking small steps forward on Monday: The biotech announced a $5 billion share-buyback plan Monday morning …
Alzheimer's Disease
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
The Motley Fool - Maxx Chatsko
Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary. When Biogen …
CVS Health
3 Top Healthcare Stocks to Buy Right Now
The Motley Fool - Keith Speights, George Budwell, and Sean Williams
What do a beaten-down biotech, a giant pharmacy chain, and a robotic surgical systems maker have in common? They could all be great stocks to …
Alzheimer's Disease
Biogen - Pipeline Setback Looks To Create An Opportunity
Seeking Alpha - The Value Investor
Just two weeks ago I looked at Biogen (BIIB) as it was "adding to the pipeline" with the acquisition of Nightstar Therapeutics (NITE) in an $800 …
Investing
Akebia Therapeutics: Still A Buy Post-Merger
Seeking Alpha - Elle Investments
Source: AKBA website On March 18, Akebia Therapeutics (NASDAQ:AKBA) announced preliminary results for the full-year 2018. This was its first …
Investing
Lexicon Pharmaceuticals Knocked Back By The FDA's Rejection Of Zynquista
Seeking Alpha - Stephen Simpson, CFA
Once again the FDA has shown that when it comes to new therapies for diabetes, particularly Type 1 diabetes, the agency believes in an abundance …
Investing
Can You Win With Portola Pharmaceutical Options?
Seeking Alpha - Fred Campbell
I will begin by saying I generally write exclusively on conservative investments, usually bank stocks. There is a reason for this as I know almost …
Investing
PDL BioPharma: Analysis Of Q4 2018 - Taking Some Profits Here
Seeking Alpha - Adam Stich
Spearheaded with a $100 million buyback program, PDL BioPharma (PDLI) had a nearly 40% run up from September until the end of March. At this point, I …
Investing
4 Blockbuster Drug Launches to Watch in 2019
The Motley Fool - Cory Renauer
These four experimental drugs will reach the market soon, and the companies launching them have little room for error. Get ready for some blockbuster …
Investing
2 High-Growth Stocks I'd Buy Right Now
The Motley Fool - George Budwell
Catalyst Pharmaceuticals and HEXO could both be on the verge of a long-tailed growth trend. With the economy showing signs of cooling off, investors …
Investing
Is This Under-the-Radar Biotech Stock a Buy Near an All-Time High?
The Motley Fool - Maxx Chatsko
Repligen has grown product revenue 220% since 2014, but it trades at 70 times future earnings. What should investors make of that? Most investors have …
Investing
Xenon Pharmaceuticals: Updates To Thesis, Pipeline Progressing
Seeking Alpha - Jonathan Faison
Shares of Xenon Pharmaceuticals (XENE) rose by as much as 150% a couple quarters after my May 2018 Reader Inquiry piece was published (thanks to ROTY …
New Jersey
Catalyst Pharma adds to rally on Firdapse outlook, up 15%
Seeking Alpha - Douglas W. House
Catalyst Pharmaceuticals (CPRX +14.7%) is up on 50% higher volume. Shares have rallied over 50% since last week when it delivered a corporate …
NantKwest up 30% on $39M Soon-Shiong investment
Seeking Alpha - Douglas W. House
Thinly traded micro cap NantKwest (NK +30.2%) is up almost a 12x surge in volume following its announcement that Chairman & CEO Patrick Soon-Shiong, …
Nasdaq
Curis leads healthcare gainers; Recro Pharma and Sorrento Therapeutics among losers
Seeking Alpha - Akanksha Bakshi
Gainers: Curis (NASDAQ:CRIS) +47%. NantKwest (NASDAQ:NK) +31%. Axsome Therapeutics (NASDAQ:AXSM) +17%. Check-Cap (NASDAQ:CHEK) +13%. Catalyst …
Johnson & Johnson
Bayer and J&J to settle Xarelto suits for $775M
Seeking Alpha - Douglas W. House
Despite prevailing in six cases that went to trial, Bayer (OTCPK:BAYRY -2.4%) and Johnson & Johnson (JNJ -0.3%) unit Janssen Pharmaceuticals have …
Investing
Summit Therapeutics Has Started Attracting Institutional Investors Again
Seeking Alpha - Trent Welsh
Summit Therapeutics (SMMT) is focused on its lead candidate ridinilazole for C. difficile infection or CDI along with its antibiotic pipeline via its …
New Orleans, LA
Ascendis Pharma up 2% on positive TransCon data
Seeking Alpha - Douglas W. House
Ascendis Pharma A/S (ASND +1.6%) is up on light volume in response to positive topline results from a Phase 3 clinical trial, heiGHt, evaluating …
New Orleans, LA
Strongbridge Bio up 8% premarket
Seeking Alpha - Douglas W. House
Strongbridge Biopharma (NASDAQ:SBBP) is up 8% premarket on light volume on the heels of new analyses from the open-label Phase 3 SONICS study of …
Curis up 73% on sale of portion of Erivedge royalties
Seeking Alpha - Douglas W. House
Thinly traded nano cap Curis (NASDAQ:CRIS) is up 73% premarket on robust volume in response to its agreement to sale of a portion of global royalties …
Type 1 Diabetes
What's Next for Lexicon Pharmaceuticals?
The Motley Fool - Maxx Chatsko
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue. The U.S. …
Investing
3 Stocks to Buy Ahead of the Next Market Crash
The Motley Fool - George Budwell, Keith Noonan, and Jeremy Bowman
BioMarin, Waste Management, and Walmart are three top defensive picks worth buying now. With a growing number of economists predicting a recession in …
Investing
Alibaba and Amarin Among Unanimous Strong Buy Stocks
TheStreet - Tip Ranks
When analysts do agree on a particular stock, you know you've got something special. Here we will take a look at three stocks that have elicited …
The Brain
From bats to bacteria: what scientists think might cause and stop Alzheimer’s
MarketWatch - By Dr. Craig Bowron
This article is reprinted by permission from NextAvenue.org. Alzheimer’s disease is the most frequent form of dementia, and it is both cruel and …
In Vivo
Thermo Fisher buys Brammer Bio for $1.7B
Seeking Alpha - Carl Surran
Thermo Fisher (NYSE:TMO) agrees to acquire Brammer Bio for ~$1.7B in cash in a bid to expand its presence in the gene therapy field. Brammer Bio, …
Investing
Dermira launches a campaign to highlight QBREXZA cloth
Seeking Alpha - Mamta Mayani
Dermira (NASDAQ:DERM) has launched “Life Unfolds,” a new direct-to-consumer creative campaign designed to generate awareness of QBREXZA …
New Orleans, LA
Ascendis Pharma reports positive data from phase 3 heiGHt trial
Seeking Alpha - Mamta Mayani
Ascendis Pharma A/S (NASDAQ:ASND) announces top-line results from its phase 3 heiGHt Trial, presented at the Endocrine Society’s annual meeting, ENDO …